A report by MAP BioPharma has found that NICE’s appraisal of rare disease medicines does not deliver equal access for patients.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.